| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22061 |
| Drug | Faricimab |
| Brand | Vabysmo ® |
| Indication | For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO). |
| Assessment Process | |
| Rapid review commissioned | 29/08/2022 |
| Rapid review completed | 04/10/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab (Vabysmo®) for the treatment of DMO compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 25/10/2022 |
| Pre-submission consultation with Applicant | 03/10/2023 |
| Full submission received from Applicant | 12/06/2024 |
| Preliminary review sent to Applicant | 20/03/2025 |
| NCPE assessment re-commenced | 16/04/2025 |
| Factual accuracy sent to Applicant | 06/06/2025 |
| NCPE assessment re-commenced | 13/06/2025 |
| NCPE assessment completed | 01/07/2025 |
| NCPE assessment outcome | The NCPE recommends that faricimab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.